MADRIGAL PHARMACEUTICALS INC

NASDAQ: MDGL (Madrigal Pharmaceuticals, Inc.)

Last update: 14 hours ago

400.10

-0.33 (-0.08%)

Previous Close 400.43
Volume 857,686
Price / Earnings (Forward) 57.62
Price / Sales 6.47
Price / Book 14.83
52 Weeks Range
353.54 (-11%) — 615.00 (53%)
Profit Margin -123.38%
Operating Margin (TTM) -57.79%
Diluted EPS (TTM) -17.83
Total Debt/Equity (MRQ) 16.85%
Current Ratio (MRQ) 5.91
Operating Cash Flow (TTM) -395.31 M
Levered Free Cash Flow (TTM) -274.11 M
Return on Assets (TTM) -25.56%
Return on Equity (TTM) -50.16%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Madrigal Pharmaceuticals, Inc. Mixed Bullish

AIStockmoo Score

-0.2
Analyst Consensus 0.0
Insider Activity NA
Price Volatility 5.0
Technical Moving Averages -2.5
Technical Oscillators -2.5
Relative Valuation NA
Financial Health 0.0
Macro Environment -1.3
AI Insight NA
AI Technical NA
Weighted Average -0.24

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
MDGL - - - 14.83
FOLD 5 B - - -
HUMA - - - 4.00
ABUS - - - 2.97
PLUR - - - -
CYTK - - - -

Select this tab to load the latest available analysis.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 7.73%
% Held by Institutions 108.28%

No data within this time range.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria